RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Frontiers | Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update | Cardiovascular Medicine
REDUAL PCI dual antithrombotic therapy with dabigatran after
Atrial Fibrillation and PCI - ppt download
Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI - ScienceDirect
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? - European
Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy | AETOSWire
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
REC: Interventional Cardiology - Special article
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. - Abstract - Europe PMC
![AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183](http://medline.org.cn/ueditor/jsp/upload/image/20171116/1510827731603053890.png "AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183")
AHA2017]RE-DUAL PCI：达比加群双疗治疗亚组分析，获益依旧】-中华医学网-183
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. - Abstract - Europe PMC
Anticoagulation in patients with non-valvular AF undergoing PCI: clinical evidence from PIONEER AF-PCI - The British Journal of Cardiology
Dalla non inferiorita alla superiorita i NAO sono
PCRonline - The RE-DUAL PCI trial subanalysis: In spite of... | Facebook
Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients
Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug? | Semantic
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
Dual Antithrombotic Therapy with Dabigatran after PCI ... | GrepMed
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation | Challenges in Cardiology
PDF) Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in
redual - Twitter Search / Twitter
